Proteome and Transcriptome Markers of Hypertension in Urine and Plasma Exosomes

尿液和血浆外泌体中高血压的蛋白质组和转录组标志物

• 批准号: 7815243
• 负责人: Kevin L Schey
• 金额: $ 45.78万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7815243
• 关键词: Antibodies; Biological Markers; Biology; Blood; Blood Proteins; Blood specimen; Caliber; Cardiovascular Diseases; Cell Separation; Cells; Classification; Collection; Correlation Studies; Data; Development; Diagnosis; Diagnostic; Diet; Disease; Future; Gene Expression Profile; Goals; Heart failure; High Prevalence; Human; Hypertension; Inflammatory; Kidney Failure; Lead; Lipids; Malignant Neoplasms; Measurement; Measures; Medicine; Membrane; Methodology; Methods; Molecular Analysis; Monitor; Patients; Penetration; Performance; Phenotype; Plasma; Prediction of Response to Therapy; Protein Analysis; Proteins; Proteome; Proteomics; Protocols documentation; RNA; RNA analysis; Research; Ribonucleases; Sampling; Sensitivity and Specificity; Serum; Serum Albumin; Shotguns; Sodium Chloride; Sorting - Cell Movement; Source; Specificity; Stroke; Technology; Therapeutic; Therapeutic Intervention; Time; Tissues; Urine; Vesicle; base; design; human subject; hypertension treatment; improved; meetings; molecular marker; novel; novel marker; novel strategies; outcome forecast; particle; patient population; prognostic; public health relevance; response; salt sensitive; success; therapy development; tool; transcriptomics; urinary; vector

DESCRIPTION (provided by applicant): The promise of biomarker discovery leading to personalized medicine, i.e. improved diagnosis and prognosis, has been widely disseminated and has met with mild success, at best. The most common tool used for biomarker discovery is plasma proteomics because of the accessibility of blood samples and the rapid development of highly sensitive proteomics technologies. The major obstacle for biomarker discovery in plasma samples is the well known dynamic range issue where highly abundant proteins such as serum albumin are 1010 times more abundant than the least concentrated, perhaps most important, marker proteins. The proposed research plan outlines a fundamentally different and novel strategy that combines both transcriptomic and proteomic methodologies that is designed to circumvent the dynamic range issue in plasma proteomics. The specific goal of the proposed research is to develop a combined transcriptomic and proteomics approach to measure disease specific RNA and protein signatures in isolated plasma microvesicles and urinary exosomes. These lipid particles contain both protein and RNA and are known to be secreted at higher rates in cancer and inflammatory diseases; hence, they are currently being investigated as biomarker vectors. The proposed complementary strategy of protein and RNA analysis provides a powerful synergistic approach for elucidating disease- specific signatures with high specificity and sensitivity. To further increase analytical specificity, cell- and tissue-specific microparticles will be isolated from plasma and urine samples to acquire diagnostic markers, mechanistic information, and markers to monitor therapeutic response. Finally, biomarkers will be identified and validated in hypertension, a common human condition, which contributes to the enormous burden of stroke, heart failure, and renal failure unless treated. Hypertensive subjects will be subjected to controlled diet for classification of salt-sensitivity and plasma and urine collection for subsequent molecular analysis and statistical correlation. It is anticipated that a panel of novel biomarkers (both protein and RNA) will be discovered and validated as markers for diagnostic, prognostic, and therapeutic response that will enable improved treatment of hypertension. PUBLIC HEALTH RELEVANCE: The goal of the proposed research is to develop a novel method for discovery of molecular markers of disease that circumvents existing obstacles. Through analysis of proteins and RNA found in lipid particles isolated from blood and urine, new markers of disease will be discovered that improve diagnosis, prognosis, and prediction of response to therapy; that is, improve personalized medicine. The new methodology will be applied to reveal biomarkers of salt- sensitivity and therapeutic response in hypertensive subjects.

描述（由申请人提供）：生物标志物发现的前景导致个性化医疗，即改善诊断和预后，已被广泛传播，并取得了轻微的成功，充其量。用于生物标志物发现的最常见的工具是血浆蛋白质组学，因为血液样品的可获得性和高灵敏度蛋白质组学技术的快速发展。在血浆样品中发现生物标志物的主要障碍是众所周知的动态范围问题，其中高度丰富的蛋白质如血清白蛋白比最低浓度的、可能是最重要的标志物蛋白质丰富1010倍。拟议的研究计划概述了一个根本不同的和新的策略，结合转录组学和蛋白质组学的方法，旨在规避血浆蛋白质组学的动态范围问题。拟议研究的具体目标是开发一种组合的转录组学和蛋白质组学方法，以测量分离的血浆微泡和尿外泌体中的疾病特异性RNA和蛋白质特征。这些脂质颗粒含有蛋白质和RNA，并且已知在癌症和炎性疾病中以更高的速率分泌;因此，它们目前正在作为生物标志物载体进行研究。所提出的蛋白质和RNA分析的互补策略提供了用于阐明具有高特异性和灵敏度的疾病特异性特征的强有力的协同方法。为了进一步提高分析特异性，将从血浆和尿液样品中分离细胞和组织特异性微粒，以获得诊断标志物、机制信息和监测治疗反应的标志物。最后，将在高血压中鉴定和验证生物标志物，高血压是一种常见的人类疾病，除非治疗，否则会导致中风，心力衰竭和肾衰竭的巨大负担。高血压受试者将接受控制饮食以进行盐敏感性分类，并采集血浆和尿液用于后续分子分析和统计相关性。预计一组新的生物标志物（蛋白质和RNA）将被发现和验证为诊断，预后和治疗反应的标志物，这将使高血压的治疗得到改善。 公共卫生关系：这项研究的目标是开发一种新的方法来发现疾病的分子标记物，从而绕过现有的障碍。通过分析从血液和尿液中分离出的脂质颗粒中发现的蛋白质和RNA，将发现新的疾病标志物，从而改善诊断、预后和对治疗反应的预测;也就是说，改善个性化医疗。新的方法学将应用于揭示高血压患者盐敏感性和治疗反应的生物标志物。